Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
about
Protein aggregation and its impact on product qualityTrace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins.Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality.Therapeutic protein aggregation: mechanisms, design, and control.Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?Careful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment.Anemia of renal disease: what it is, what to do and what's new.From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.The use of darbepoetin to stimulate erythropoiesis in anemia of chronic kidney disease in cats: 25 cases.Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity.Anti-epoetin-antibody-induced anemia in a child with chronic renal failure.Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia.A survey of applications of biological products for drug interference of immunogenicity assays.Biologics: structural heterogeneity and immunogenicity.Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys.Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia.
P2860
Q27010661-45A55DAA-77C1-41A2-B17A-50717F638D9CQ33784812-7045479E-FBE8-4DBD-B276-0C9934C93913Q33804009-C7B3E7D4-54F7-464F-A656-C4AF6A368EF2Q33850993-DD067FE7-1FDD-457B-9A05-D1D274AABCD1Q34097620-87101BF1-B69D-405E-9DA7-54FBF3991037Q35573764-C85E2345-7A09-4CA1-A04F-D4C2C86AD78DQ36511739-BBF4130C-1766-4A2F-9263-5F768D03FB7AQ37923100-31C0CB43-3177-46F8-B4EE-F1737A4318DBQ38644644-DF9233F4-774C-4194-84F5-7785237EDE99Q38763700-7806DC5F-97EE-4733-808D-916A6B86961EQ40297731-AC2D2898-5C51-400F-A5B1-5A0513040D39Q41944133-2DA1F948-E599-4EA7-A139-8B2AAD44A0B6Q42870448-C17A87F5-2FCE-4566-B2B8-B07BE88884DCQ43064681-5274C107-34F1-4398-B847-481980F3DEDDQ47247174-4DFD469B-F4A3-47E9-8FA3-26B11E513185Q47983376-DDB21E70-D325-4E69-82B9-6F7476BD1CDEQ50581034-29BF30EA-C29D-45BB-A98C-10C50635BA42Q50654749-3A65D71E-8E04-4842-90E3-3AC9BA68FC24
P2860
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
@ast
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
@en
type
label
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
@ast
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
@en
prefLabel
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
@ast
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
@en
P356
P1476
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
@en
P2093
Iain C Macdougall
P304
P356
10.1093/NDT/GFH1087
P407
P478
20 Suppl 4
P577
2005-05-01T00:00:00Z